Detail akcie Ultragenyx Pharm online

Business Summary: Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel products for the treatment of serious rare and ultra-rare genetic diseases. The Company's clinical-stage pipeline consists of four product categories: biologics, small molecules, AAV gene therapy, and nucleic acid product candidates. Its products include Crysvita (burosumab), Mepsevii (vestronidase alfa), Dojolvi (triheptanoin), and Evkeeza (evinacumab). Crysvita is used for the treatment of X-linked hypophosphatemia, or XLH, in adult and pediatric patients one year of age and older. Mepsevii is used for the treatment of children and adults with mucopolysaccharidosis VII, or MPS VII, also known as Sly syndrome. Dojolvi is used for the treatment of pediatric and adult patients severely affected by long-chain fatty acid oxidation disorders, or LC-FAOD. Evkeeza is used for the treatment of homozygous familial hypercholesterolemia, or HoFH.
Financial Summary: BRIEF: For the six months ended 30 June 2026, Ultragenyx Pharmaceutical Inc revenues increased 14% to $350M. Net loss increased 4% to $277M. Revenues reflect Crysvita non-cash collaboration royalty revenue segment increase of 12% to $149M, Evkeeza segment increase of 52% to $39M, North America segment increase of 12% to $180M, Latin America segment increase of 6% to $93M.